Future of drug development: The economics of pharmacogenomics

Expert Review of Clinical Pharmacology

Volumn 1, Issue 1, 2008, Pages 49-59

  Vernon, John A ^a   Hughen, Keener ^b   Golec, Joseph H ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; THALIDOMIDE; TRASTUZUMAB;

ARTICLE; BIRTH DEFECT; BREAST CANCER; CLINICAL RESEARCH; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; GENE OVEREXPRESSION; GENETIC MARKER; HEALTH ECONOMICS; HIGH RISK PATIENT; HUMAN; INVESTMENT; MATHEMATICAL MODEL; MORNING SICKNESS; PHARMACOGENOMICS; PROBABILITY; RISK BENEFIT ANALYSIS; SOCIAL WELFARE;

EID: 38349070534     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.1.49     Document Type: Article

References (18)

1. DiMasi, JA, Hansen RW, Grabowski HG. 'Extraordinary claims require extraordinary evidence' reply to Light and Warburton. J. Health Econ. 24(5), 1034-1044 (2005).
2. Golec JH, Vernon JA. What's at stake in pharmaceutical reimportation: the costs in terms of life years, lives, and dollars. J. Law Public Policy (16)1, 135-149 (2005).
3. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
4. Mattingly S. Really personal medicine. Natl J. Technol. Commercialization 26-28 (2004).
5. Quintiles transnational. Personalized Medicine: the Emerging Pharmacogenomics Revolution. PriceWaterHouseCoopers, Global Technology Center, Health Research Institute (2005).
6. Phillips KA, Veenstra DL, Sadee W, Oren E, Lee JK. The potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286(18), 2270-2279 (2001).
7. Vernon JA, Hughen WK, Johnson S, Trujillo A. Economic and developmental considerations for of pharmacogenomic technology. Pharmacoeconomics 24(4), 335-343 (2005).
8. Lichtenberg FR. Sources of U.S. longevity increase, 1960-1997. Working Paper 8755. National Bureau of Economic Research, MA, USA (2002).
9. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff. 20(5), 11-29 (2001).
10. Murphy KM, Topel RH. The economic value of medical research. In: Measuring the Gains from Medical Research. Murphy KM, Topel RH (Eds). The University of Chicago Press, Chicago, IL, USA 41-73 (2003).
11. DiMasi JA, Hansen RW, Grabowski HG. 'Setting the record straight on setting the record straight: response to the Light and Warburton rejoinder'. J. Health Econ. 24(5), 1049-1053 (2005).
12. Light DW, Warburton RN. Extraordinary claims require extraordinary evidence. J. Health Econ. 24(5), 1030-1033 (2005).
13. Light DW, Warburton RN. Setting the record straight in the reply by DiMasi, Hansen and Grabowski. J. Health Econ. 24(5), 1045-1048 (2005).
14. Guo Y, Shafer S, Weller P et al. Pharmacogenomics and drug development. Pharmacogenomics 6, 857-864 (2005).
15. Trepicchio WL, Essayan D, Hall ST et al. Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making. Pharmacogenomics J. 6, 89-94 (2006).
16. Ginsburg GS, Konstance RP, Allsbrooks JS et al. Implications of pharmacogenomics for drug development and clinical practice. Arch. Intern. Med. 65, 2331-2336 (2005).
17. McCamish M, Izumi R. Perspectives on development of a combination pharmacogenomic diagnostic and drug product. Pharmacogenomics 7, 1045-1049 (2006).
18. Stallings SC, Huse D, Finkelstein SN et al. A framework to evaluate the economic impact of pharmacogenomics. Pharmacogenomics 7, 853-862 (2006).